Additionally, the CCK-8 assay confirmed a decline in HCC cell viability following sorafenib treatment, with the decrease more pronounced in the HCC cells of the si-TMEM39b group (Figs. 5H and 5I). This evidence concerns the gene TMEM39B and hepatocellular carcinoma.